Amgen announces EMA acceptance of Kyprolis (Carfilzomib) MAA tor relapsed multiple myeloma
Amgen and subsidiary Onyx Pharma, announced the EMA has accepted the Marketing Authorization Application of Kyprolis® (carfilzomib) for Injection for treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The MAA was granted accelerated assessment. February 26, 2015